Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27146276 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Marzia Pucci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy. Hauptthemen laut MEDLINE: Extracellular Vesicles, Multiple Myeloma, Immunomodulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, European Union—NextGenerationEU—PNRR M6C2—Investment 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN—Italian Ministry of Health.
Abstract (Originalsprache)
Multiple myeloma (MM) is a genetically and clinically heterogeneous plasma cell malignancy characterised by clonal expansion of differentiated B cells within the bone marrow (BM). Patients start with monoclonal gammopathy of undetermined significance (MGUS) and progress to an intermediate stage called smouldering multiple myeloma (SMM), characterised by several genetic alterations that represent the genomic backbone of the malignant clone. Immune checkpoint pathways play a central role in shaping an immunosuppressive BM niche, contributing to T-cell dysfunction, immune evasion, and therapeutic resistance. Key inhibitory receptors such as PD-1, CTLA-4, TIM-3, LAG-3, and CD47 are frequently dysregulated, promoting T-cell exhaustion, anergy, and senescence. Emerging evidence highlights extracellular vesicles (EVs) as critical mediators of intercellular communication in MM. MM-derived EVs carry bioactive cargo, including proteins and miRNAs, that reprogram immune and stromal cells, enhancing tumour progression and immune escape. Notably, EV-associated immune checkpoint molecules contribute to the establishment of a permissive microenvironment. This review provides an integrated overview of immune checkpoint dysregulation and EV-mediated immunomodulation in MM, emphasising their role in disease pathogenesis and progression. Furthermore, we discuss the therapeutic potential of targeting immune checkpoints and exploiting EVs as novel biomarkers and drug delivery systems, highlighting their promise for improving precision medicine approaches in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy.
- Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy.
ORCID-Profile: Marzia Pucci, Elisa Costanzo, Martina Marfia, Simona Fontana, Chiara Corrado, Riccardo Alessandro
Förderung
- Ministry of Health
- European Union—NextGenerationEU—PNRR M6C2—Investment 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN—Italian Ministry of Health
Zitieren
APA
Pucci, M., Costanzo, E., Marfia, M., Seidita, G., Fontana, S., Corrado, C., & Alessandro, R. (2026). Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27146276
Vancouver
Pucci M, Costanzo E, Marfia M, Seidita G, Fontana S, Corrado C, et al. Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27146276
BibTeX
@article{Pucci2026,
author = {Pucci, Marzia and Costanzo, Elisa and Marfia, Martina and Seidita, Gregorio and Fontana, Simona and Corrado, Chiara and Alessandro, Riccardo},
title = {Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27146276}
}
EUVIMED